The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-κB canonical signaling pathway in PMA-induced THP-1 monocytes

International Journal of Molecular Medicine

Volumn 27, Issue 2, 2011, Pages 233-241

  Wang, Yue ^a   Huang, Zhouqing ^a,b   Wang, Liansheng ^a   Meng, Shu ^a   Fan, Yuqi ^a   Chen, Ting ^a   Cao, Jiatian ^a   Jiang, Rujia ^a   Wang, Changqian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Artemisinin; Atherosclerosis; Inflammation; Monocytes; NF B

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 O METHYLPHORBOL 13 ACETATE 12 MYRISTATE; ARTEMISININ; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BINDING ASSAY; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; HUMAN; HUMAN CELL; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; ARTEMISININS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; MONOCYTES; NF-KAPPA B; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 78650656795     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2010.580     Document Type: Article

References (44)

1. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
2. Hansson GK: Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
3. Takahashi K, Takeya M and Sakashita N: Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals. Med Electron Microsc 35: 179-203, 2002. (Pubitemid 36205679)
4. Lessner SM, Prado HL, Waller EK and Galis ZS: Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol 160: 2145-2155, 2002.
5. Osterud B and Bjorklid E: Role of monocytes in atherogenesis. Physiol Rev 83: 1069-1112, 2003.
6. Shashkin P, Dragulev B and Ley K: Macrophage differentiation to foam cells. Curr Pharm Des 11: 3061-3072, 2005.
7. Tabas I: Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 25: 2255-2264, 2005.
8. Chen JW, Chen YH and Lin SJ: Long-term exposure to oxidized low-density lipoprotein enhances tumor necrosis factor-alpha-stimulated endothelial adhesiveness of monocytes by activating superoxide generation and redox-sensitive pathways. Free Radic Biol Med 40: 817-826, 2006.
9. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
10. Meshnick SR, Taylor TE and Kamchonwongpaisan S: Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60: 301-315, 1996.
11. Haynes RK: Artemisinin and derivatives: the future for malaria treatment? Curr Opin Infect Dis 14: 719-726, 2001.
12. Wang JX, Tang W, Shi LP, Wan J, Zhou R, Ni J, Fu YF, Yang YF, Li Y and Zuo JP: Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 150: 652-661, 2007. (Pubitemid 46355561)
13. Wang Z, Qiu J, Guo TB, Liu A, Wang Y, Li Y and Zhang JZ: Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J Immunol 179: 5958-5965, 2007.
14. Wang J, Zhou H, Zheng J, Cheng J, Liu W, Ding G, Wang L, Luo P, Lu Y, Cao H, Yu S, Li B and Zhang L: The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing pro-inflammatory cytokine release. Antimicrob Agents Chemother 50: 2420-2427, 2006.
15. Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F and Sun L: Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 46: 920-926, 2007.
16. Hou J, Wang D, Zhang R and Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization and mechanisms of action. Clin Cancer Res 14: 5519-5530, 2008.
17. Dell'Eva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A and Efferth T: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68: 2359-2366, 2004.
18. D'Angelo JG, Bordón C, Posner GH, Yolken R and Jones-Brando L: Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. J Antimicrob Chemother 63: 146-150, 2009.
19. Auwerx J: The human leukemia cell line, THP-1: a multifaceted model for the study of monocyte-macrophage differentiation. Experientia 47: 22-31, 1991.
20. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T and Tada K: Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 42: 1530-1536, 1982.
21. Requena P, Daddaoua A, Guadix E, Zarzuelo A, Suárez MD, Sánchez de Medina F and Martínez-Augustin O: Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. Br J Pharmacol 157: 1232-1240, 2009.
22. Musa H, Meek S, Gautel M, Peddie D, Smith AJ and Peckham M: Targeted homozygous deletion of M-band titin in cardiomyocytes prevents sarcomere formation. J Cell Sci 119: 4322-4331, 2006.
23. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H and Bensi G: Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13: 6231-6240, 1993. (Pubitemid 23292617)
24. Libermann TA and Baltimore D: Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10: 2327-3234, 1990.
25. Son YH, Jeong YT, Lee KA, Choi KH, Kim SM, Rhim BY and Kim K: Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol 51: 71-77, 2008.
26. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA and Jongeneel CV: Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171: 35-47, 1990.
27. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB and Pahor M: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108: 2317-2322, 2003.
28. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG and Lip GY: Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 33: 941-948, 2003.
29. Kaul N, Devaraj S and Jialal I: α-Tocopherol and atherosclerosis. Exp Biol Med (Maywood) 226: 5-12, 2001.
30. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y and Lowe GD: The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis 209: 551-557, 2009.
31. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariéty J and Nicoletti A: In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104: 197-202, 2001.
32. Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J and Jovinge S: Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24: 2137-2142, 2004.
33. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A and Ghigo D: Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett 552: 141-144, 2003.
34. Liao F, Andalibi A, deBeer FC, Fogelman AM and Lusis AJ: Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 91: 2572-2579, 1993. (Pubitemid 23182511)
35. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T and Cybulsky MI: The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97: 9052-9057, 2000.
36. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M and Egido J: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532-1541, 1997.
37. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ and Schwartz MA: The subendothelial extracellular matrix modulates NF-kappaB activation by flow: a potential role in atherosclerosis. J Cell Biol 169: 191-202, 2005.
38. Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
39. Yamamoto Y and Gaynor RB: IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 29: 72-79, 2004.
40. Karin M and Lin A: NF-kappa B at the crossroads of life and death. Nat Immun 3: 221-227, 2002.
41. Baldwin AS: The transcription factor NF-kappa B and human disease. J Clin Invest 107: 3-6, 2001.
42. Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109: S81-S96, 2002.
43. Cordle SR, Donald R, Read MA and Hawiger J: Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-kappa B proteins in human monocytic THP-1 cells. J Biol Chem 268:11803-11810, 1993.
44. López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J and Gómez- Guerrero C: Parthenolide modulates the NF-κB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 26: 1864-1870, 2006.